Shijiazhuang Yiling Pharmaceutical Co., Ltd.
Simbols: 002603.SZ
SHZ
19.58
CNYTirgus cena šodien
12.0881
P/E koeficients
1.2606
PEG koeficients
32.71B
MRK Cap
- 0.03%
DIV ienesīgums
Shijiazhuang Yiling Pharmaceutical Co., Ltd. (002603-SZ) Finanšu pārskati
Bilance
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 8322.47 | 2422.7 | 1050.5 | 1554 | |||||||||||||||
balance-sheet.row.short-term-investments | 2554.79 | 518.4 | 55.3 | 217 | |||||||||||||||
balance-sheet.row.net-receivables | 11259.24 | 2699.6 | 2593.1 | 2102.4 | |||||||||||||||
balance-sheet.row.inventory | 9782.92 | 2021.8 | 1672.7 | 1580.3 | |||||||||||||||
balance-sheet.row.other-current-assets | 631.46 | 110.1 | 285.8 | 222.7 | |||||||||||||||
balance-sheet.row.total-current-assets | 29996.09 | 7254.2 | 5602.1 | 5459.4 | |||||||||||||||
balance-sheet.row.property-plant-equipment-net | 26574.19 | 6221.8 | 5745.5 | 4299.1 | |||||||||||||||
balance-sheet.row.goodwill | 228.47 | 0 | 0 | 0 | |||||||||||||||
balance-sheet.row.intangible-assets | 3445.29 | 828 | 897.9 | 736.6 | |||||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 3673.77 | 828 | 897.9 | 736.6 | |||||||||||||||
balance-sheet.row.long-term-investments | 4655.45 | 830.5 | -54.3 | -216 | |||||||||||||||
balance-sheet.row.tax-assets | 820.62 | 279.9 | 117 | 137.8 | |||||||||||||||
balance-sheet.row.other-non-current-assets | 4451.29 | 921.8 | 596.6 | 1075.3 | |||||||||||||||
balance-sheet.row.total-non-current-assets | 40175.32 | 9081.9 | 7302.7 | 6032.9 | |||||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||||||||||
balance-sheet.row.total-assets | 70171.42 | 16336.1 | 12904.8 | 11492.3 | |||||||||||||||
balance-sheet.row.account-payables | 10015.9 | 2060.8 | 1621.2 | 1188.4 | |||||||||||||||
balance-sheet.row.short-term-debt | 3422.6 | 656.3 | 513.9 | 270.2 | |||||||||||||||
balance-sheet.row.tax-payables | 1098.62 | 474 | 123.2 | 133.9 | |||||||||||||||
balance-sheet.row.long-term-debt-total | 1455.8 | 215.1 | 513 | 10.5 | |||||||||||||||
Deferred Revenue Non Current | 1400.88 | 335 | 357.8 | 328.1 | |||||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 263.2 | - | - | - | |||||||||||||||
balance-sheet.row.other-current-liab | 1781.83 | 1027.3 | 216.3 | 28.3 | |||||||||||||||
balance-sheet.row.total-non-current-liabilities | 3119.87 | 555.7 | 872.2 | 330.1 | |||||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||||||||||
balance-sheet.row.capital-lease-obligations | 54.95 | 15 | 12.5 | 10.5 | |||||||||||||||
balance-sheet.row.total-liab | 23563.79 | 5405.8 | 3832.7 | 2569 | |||||||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | |||||||||||||||
balance-sheet.row.common-stock | 6682.82 | 1670.7 | 1670.7 | 1203.7 | |||||||||||||||
balance-sheet.row.retained-earnings | 26853.23 | 5989.2 | 4306.2 | 4324.4 | |||||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 8524.94 | 989 | 808.9 | 640.9 | |||||||||||||||
balance-sheet.row.other-total-stockholders-equity | 4566.63 | 2283.3 | 2283.3 | 2750.3 | |||||||||||||||
balance-sheet.row.total-stockholders-equity | 46627.62 | 10932.2 | 9069.1 | 8919.3 | |||||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 70171.42 | 16336.1 | 12904.8 | 11492.3 | |||||||||||||||
balance-sheet.row.minority-interest | -19.99 | -1.9 | 3 | 4.1 | |||||||||||||||
balance-sheet.row.total-equity | 46607.63 | 10930.3 | 9072.2 | 8923.4 | |||||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 70171.42 | - | - | - | |||||||||||||||
Total Investments | 7210.24 | 1348.9 | 1 | 1 | |||||||||||||||
balance-sheet.row.total-debt | 4878.39 | 871.4 | 1026.9 | 270.2 | |||||||||||||||
balance-sheet.row.net-debt | -889.29 | -1032.8 | 31.6 | -1066.8 |
Naudas plūsmas pārskats
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 2706.16 | 2356.8 | 1341.6 | 1214.9 | |||||||||||||||
cash-flows.row.depreciation-and-amortization | 121.87 | 451.5 | 362.9 | 268.2 | |||||||||||||||
cash-flows.row.deferred-income-tax | 0 | -158.7 | 20.1 | -67.7 | |||||||||||||||
cash-flows.row.stock-based-compensation | 0 | 158.7 | -20.1 | 67.7 | |||||||||||||||
cash-flows.row.change-in-working-capital | -1179.67 | 547.8 | -1309.7 | 24.8 | |||||||||||||||
cash-flows.row.account-receivables | -831.66 | -831.7 | -1280.3 | -668.7 | |||||||||||||||
cash-flows.row.inventory | -348.01 | -348 | -104.7 | -364.9 | |||||||||||||||
cash-flows.row.account-payables | 22.82 | 1886.2 | 55.1 | 1126.1 | |||||||||||||||
cash-flows.row.other-working-capital | -22.82 | -158.7 | 20.1 | -67.7 | |||||||||||||||
cash-flows.row.other-non-cash-items | 245.91 | 131.6 | 133.9 | 78.3 | |||||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 1894.27 | 0 | 0 | 0 | |||||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | -246.9 | -214 | -673.6 | -1144.8 | |||||||||||||||
cash-flows.row.acquisitions-net | -628.54 | 0.4 | 2.4 | 1145.1 | |||||||||||||||
cash-flows.row.purchases-of-investments | -5902.36 | -3461.9 | -451 | -2853.3 | |||||||||||||||
cash-flows.row.sales-maturities-of-investments | 4047.54 | 1680.7 | 616.6 | 2957.6 | |||||||||||||||
cash-flows.row.other-investing-activites | 0.36 | 0 | -1.2 | -1144.8 | |||||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | -2729.91 | -1994.8 | -506.8 | -1040.2 | |||||||||||||||
cash-flows.row.debt-repayment | -1250 | -2200 | -1469.9 | -270 | |||||||||||||||
cash-flows.row.common-stock-issued | 0 | 0 | 0 | 0 | |||||||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | 0 | |||||||||||||||
cash-flows.row.dividends-paid | -413.64 | -282.7 | -1220.1 | -244.1 | |||||||||||||||
cash-flows.row.other-financing-activites | 1321.67 | 1845.7 | 2387.9 | 490.8 | |||||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | -341.96 | -637 | -302.1 | -23.3 | |||||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0.28 | 1.2 | -0.5 | -2 | |||||||||||||||
cash-flows.row.net-change-in-cash | -663.1 | 857.2 | -280.7 | 520.8 | |||||||||||||||
cash-flows.row.cash-at-end-of-period | 5395.81 | 1810.7 | 953.5 | 1234.2 | |||||||||||||||
cash-flows.row.cash-at-beginning-of-period | 6058.9 | 953.5 | 1234.2 | 713.4 | |||||||||||||||
cash-flows.row.operating-cash-flow | 1894.27 | 3487.7 | 528.7 | 1586.2 | |||||||||||||||
cash-flows.row.capital-expenditure | -246.9 | -214 | -673.6 | -1144.8 | |||||||||||||||
cash-flows.row.free-cash-flow | 1647.37 | 3273.8 | -144.9 | 441.4 |
Peļņas vai zaudējumu aprēķina rinda
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 13161.66 | 12532.8 | 10116.8 | 8782.5 | |||||||||||||||
income-statement-row.row.cost-of-revenue | 4867.04 | 4540.6 | 3681 | 3118.4 | |||||||||||||||
income-statement-row.row.gross-profit | 8294.62 | 7992.3 | 6435.8 | 5664.1 | |||||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||||||||||
income-statement-row.row.research-development | 1074.04 | - | - | - | |||||||||||||||
income-statement-row.row.selling-general-administrative | 235.76 | - | - | - | |||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 3177.48 | - | - | - | |||||||||||||||
income-statement-row.row.other-expenses | 505.39 | 576.9 | 366.6 | 323 | |||||||||||||||
income-statement-row.row.operating-expenses | 4982.24 | 5025.8 | 4758.7 | 4179.2 | |||||||||||||||
income-statement-row.row.cost-and-expenses | 9849.29 | 9566.4 | 8439.7 | 7297.6 | |||||||||||||||
income-statement-row.row.interest-income | 14.34 | 12.9 | 20.4 | 7 | |||||||||||||||
income-statement-row.row.interest-expense | 36.75 | 33.8 | 34 | 3.8 | |||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 3177.48 | - | - | - | |||||||||||||||
income-statement-row.row.total-other-income-expensenet | -20.99 | -48.9 | -15.4 | -15.6 | |||||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||||||||||
income-statement-row.row.other-operating-expenses | 505.39 | 576.9 | 366.6 | 323 | |||||||||||||||
income-statement-row.row.total-operating-expenses | -20.99 | -48.9 | -15.4 | -15.6 | |||||||||||||||
income-statement-row.row.interest-expense | 36.75 | 33.8 | 34 | 3.8 | |||||||||||||||
income-statement-row.row.depreciation-and-amortization | 100.71 | 546.1 | 448.6 | 329.5 | |||||||||||||||
income-statement-row.row.ebitda-caps | 3303.32 | - | - | - | |||||||||||||||
income-statement-row.row.operating-income | 3202.61 | 2829.6 | 1569.1 | 1438 | |||||||||||||||
income-statement-row.row.income-before-tax | 3181.62 | 2780.6 | 1553.7 | 1422.5 | |||||||||||||||
income-statement-row.row.income-tax-expense | 482.98 | 423.8 | 212.1 | 207.5 | |||||||||||||||
income-statement-row.row.net-income | 2706.16 | 2361.8 | 1343.9 | 1218.7 |
Biežāk uzdotie jautājumi
Kas ir Shijiazhuang Yiling Pharmaceutical Co., Ltd. (002603.SZ) kopējie aktīvi?
Shijiazhuang Yiling Pharmaceutical Co., Ltd. (002603.SZ) kopējie aktīvi ir 16336112689.000.
Kādi ir uzņēmuma gada ieņēmumi?
Gada ieņēmumi ir 4639721722.000.
Kāda ir uzņēmuma peļņas norma?
Uzņēmuma peļņas norma ir 0.630.
Kāda ir uzņēmuma brīvā naudas plūsma?
Brīvā naudas plūsma ir 0.986.
Kāda ir uzņēmuma neto peļņas norma?
Neto peļņas norma ir 0.206.
Kādi ir uzņēmuma kopējie ieņēmumi?
Kopējie ieņēmumi ir 0.243.
Kāda ir Shijiazhuang Yiling Pharmaceutical Co., Ltd. (002603.SZ) tīrā peļņa (tīrie ienākumi)?
Tīrā peļņa (tīrie ienākumi) ir 2361804714.000.
Kāds ir uzņēmuma kopējais parāds?
Kopējais parāds ir 871449540.000.
Kāds ir pamatdarbības izdevumu skaits?
Darbības izdevumi ir 5025828583.000.
Kāds ir uzņēmuma skaidrās naudas rādītājs?
Uzņēmuma nauda ir 1072618858.000.